← Back to all trials
Recruiting
NCT05916963
Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser
Conditions: Kidney Stone
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 374
Sponsor: University Hospital, Tours
Location: CHU d'Angers Angers
Summary
In view of the positive results of the numerous studies conducted on forced diuresis after extra-corporeal lithotripsy, the investigators chose to evaluate forced diuresis by injection of Furosemide associated with intravenous hydration, which has never before been the subject of a specific analysis.
Eligibility Criteria
Inclusion Criteria:
* Patients ≥ 18 years old and \< 80 years old
* With the need to perform a flexible ureteroscopy with destruction of the kidney stones with laser
* Participants covered by or entitled to social security
* Written informed consent obtained from the participant
* Ability for participant to comply with the requirements of the study
Exclusion Criteria:
* Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, minors, and persons subject to a legal protection measure: guardianship or trusteeship)
* Contra-indication to Furosemide:
* Hyper-sensitivity to the active substance or one of the excipients
* Hyper-sensitivity to Sulfonamide
* Renal failure with oligo-anuria refractory to Furosemide
* Hypokalemia \< 3,5 mmol/L
* Severe hyponatremia
* Hypovolemia with or without hypotension or dehydration
* Ongoing hepatitis, hepatic insufficiency severe and hepatic encephalopathy
* Patient having Furosemide as usual treatment
* Patient requiring an injection of Aminoside or Vancomycin before or during the procedure
* Participation in other interventional research with an investigational drug or medical device
Source: ClinicalTrials.gov (NCT05916963). StuddyBuddy aggregates publicly available trial information.